Literature DB >> 1642554

Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

N Yahi1, J Fantini, I Hirsch, J C Chermann.   

Abstract

The glycoprotein precursor of the highly cytopathic Zairian virus HIV1-NDK synthesized in CEM leukemic cells displayed a molecular mass of 140 kDa (gp140) as compared to the 160 kDa of gp160 of HIV1-LAV prototype strain. This precursor was cleaved to produce a smaller than prototype extra-cellular envelope glycoprotein (gp100) and a transmembrane component with a usual size (gp41). Immunoprecipitates from tunicamycin-treated infected cells demonstrated the presence of a non-glycosylated precursor of 100 kDa for HIV1-LAV prototype strain and 90 kDa for HIV1-NDK. Digestion of labeled precipitates with a mixture of endoglycosidase F and glycopeptidase F reduced the size of HIV1-LAV gp160 and gp120 to 100 and 60 kDa, respectively, while HIV1-NDK gp140 and gp100, after treatment with the same enzymes, displayed an apparent molecular mass of 90 kDa and 55 kDa, respectively. From these data we conclude that HIV1-LAV gp120 and HIV1-NDK gp100 differ both in their proteic moiety (60 kDa and 55 kDa, respectively) and in their carbohydrate moiety (60 kDa and 45 kDa, respectively). These differences could not be deduced from the available gene sequences of the two viruses. A chimeric virus containing the first 124 amino acid residues of the envelope glycoprotein coded by HIV1-LAV sequence and the rest by HIV1-NDK displayed normal size envelope glycoproteins, demonstrating the involvement of this N-terminal sequence in the alteration of the molecular mass characteristic of HIV1-NDK gp140 and gp100. Finally, characterization of the gag gene products from both strains demonstrated that HIV1-NDK p18 and p15 have a slower electrophoretic mobility as compared to its HIV1-LAV counterparts. Therefore, structural properties of HIV1-NDK env and gag products, reflected by their unusual electrophoretic mobilities, may be responsible for HIV1-NDK biological properties.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642554     DOI: 10.1007/bf01309645

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  24 in total

Review 1.  Retrovirus envelope glycoproteins.

Authors:  E Hunter; R Swanstrom
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Human T-lymphoblastoid cells selected for growth in serum-free medium provide new tools for study of HIV replication and cytopathogenicity.

Authors:  N Yahi; J Fantini; S Baghdiguian; J C Chermann
Journal:  J Virol Methods       Date:  1991 Sep-Oct       Impact factor: 2.014

3.  Productive infection of CD4+ cells by selected HIV strains is not inhibited by anti-CD4 monoclonal antibodies.

Authors:  F Rey; G Donker; I Hirsch; J C Chermann
Journal:  Virology       Date:  1991-03       Impact factor: 3.616

4.  A chink in HIV's armour?

Authors:  P E Stephens; G Clements; G T Yarranton; J Moore
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

5.  Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus.

Authors:  B Spire; J Sire; V Zachar; F Rey; F Barré-Sinoussi; F Galibert; A Hampe; J C Chermann
Journal:  Gene       Date:  1989-09-30       Impact factor: 3.688

6.  The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site.

Authors:  M Ivey-Hoyle; R K Clark; M Rosenberg
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

7.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

8.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

9.  Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.

Authors:  R A Gruters; J J Neefjes; M Tersmette; R E de Goede; A Tulp; H G Huisman; F Miedema; H L Ploegh
Journal:  Nature       Date:  1987 Nov 5-11       Impact factor: 49.962

10.  Differences in replication and cytopathogenicity of human immunodeficiency virus type 1 (HIV-1) are not determined by long terminal repeats (LTR).

Authors:  I Hirsch; B Spire; Y Tsunetsugu-Yokota; C Neuveut; J Sire; J C Chermann
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

View more
  5 in total

1.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors:  F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  Adaptation of chimeric retroviruses in vitro and in vivo: isolation of avian retroviral vectors with extended host range.

Authors:  E V Barsov; W S Payne; S H Hughes
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

Authors:  J P Moore; Y Cao; J Leu; L Qin; B Korber; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

4.  Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Authors:  N Yahi; J Fantini; K Mabrouk; C Tamalet; P de Micco; J van Rietschoten; H Rochat; J M Sabatier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

5.  Production of a highly cytopathic HIV-1 isolate from a human mucosal epithelial cell line cultured on microcarrier beads in serum-free medium.

Authors:  N Yahi; S Baghdiguian; J Fantini
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-01       Impact factor: 2.416

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.